利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.025 秒)

    Methods and Tools for The Therapy of Neurodegenerative Pathologies
    11.
    发明申请
    Methods and Tools for The Therapy of Neurodegenerative Pathologies 审中-公开
    神经退行性病变治疗方法与工具

    公开(公告)号：US20090317842A1

    公开(公告)日：2009-12-24

    申请号：US12309492

    申请日：2007-07-20

    申请人： Fabien Schweighoffer ,  Laurent Desire ,  Jérôme Bourdin

    发明人： Fabien Schweighoffer ,  Laurent Desire ,  Jérôme Bourdin

    IPC分类号： G01N33/53 ,  C07D471/04 ,  C07D243/14

    CPC分类号： G01N33/6896 ,  G01N33/5306 ,  G01N33/9426 ,  G01N2800/2821 ,  G01N2800/52

    摘要： The present invention concerns compositions and methods for the treatment of neurodegenerative diseases in which the cognitive functions are altered, such as observed in Alzheimer's disease. More particularly, the invention presents a strategy for human clinical monitoring of the activity and/or effectiveness of neuroprotective treatments, based on biochemical assay of certain platelet parameters, and thus can be done by blood sampling. The invention also concerns methods, tools, constructions and compositions suitable for implementing these strategies.

    摘要翻译： 本发明涉及用于治疗其中认知功能改变的神经变性疾病的组合物和方法，例如在阿尔茨海默病中观察到的。 更具体地说，本发明基于某些血小板参数的生物化学测定，提出了人类临床监测神经保护治疗的活性和/或有效性的策略，因此可以通过血液取样进行。 本发明还涉及适于实施这些策略的方法，工具，构造和组合。

    Procedure and methods for detecting alzheimers's disease
    13.
    发明申请
    Procedure and methods for detecting alzheimers's disease 审中-公开
    检测阿尔茨海默病的程序和方法

    公开(公告)号：US20100055682A1

    公开(公告)日：2010-03-04

    申请号：US12227374

    申请日：2007-05-14

    申请人： Fabien Schweighoffer ,  Laurent Bracco

    发明人： Fabien Schweighoffer ,  Laurent Bracco

    IPC分类号： C12Q1/68 ,  C07H21/02 ,  C07D219/08 ,  C07D211/06 ,  C07C271/44

    CPC分类号： C12Q1/6883 ,  C12Q1/6806 ,  C12Q2600/158

    摘要： This application concerns methods and compositions that can be used for detecting the Alzheimer disease in mammals, particularly in humans. It describes in particular serum markers for Alzheimer's disease and the way they are used for diagnostic procedures. It also concerns tools and/or kits that can be used for applying these procedures (reagents, probes, primers, antibodies, chips, cells, etc.) with the preparation thereof and the way to use them. The invention can be used to detect the presence or the progression of Alzheimer illness in mammals, including at early stages of the disease.

    摘要翻译： 本申请涉及可用于检测哺乳动物，特别是人类中的阿尔茨海默病的方法和组合物。 它特别描述了阿尔茨海默病的血清标志物及其用于诊断程序的方法。 它还涉及可用于应用这些程序（试剂，探针，引物，抗体，芯片，细胞等）及其使用方法的工具和/或试剂盒。 本发明可用于检测哺乳动物中阿尔茨海默病的存在或进展，包括在疾病的早期阶段。

    Grb3-3 cDNA and polypeptides
    14.
    再颁专利
    Grb3-3 cDNA and polypeptides 失效
    Grb3-3 cDNA和多肽

    公开(公告)号：USRE37952E1

    公开(公告)日：2002-12-31

    申请号：US09641640

    申请日：2000-08-15

    申请人： Fabien Schweighoffer ,  Bruno Tocque

    发明人： Fabien Schweighoffer ,  Bruno Tocque

    IPC分类号： C07H2104

    CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K14/4705

    摘要： The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.

    摘要翻译： 本发明涉及Grb3-3蛋白，编码该蛋白质的核苷酸序列及其变体，如反义序列。 本发明还涉及包含这些序列的载体和诱导细胞死亡的方法。

    Molecular target of neurotoxicity
    15.
    发明申请
    Molecular target of neurotoxicity 审中-公开
    神经毒性的分子靶点

    公开(公告)号：US20050043319A1

    公开(公告)日：2005-02-24

    申请号：US10857455

    申请日：2004-06-01

    申请人： Fabien Schweighoffer ,  Philippe Guillet

    发明人： Fabien Schweighoffer ,  Philippe Guillet

    IPC分类号： A61K31/00 ,  C12Q1/44 ,  C12Q1/68 ,  A61K31/519 ,  A61K31/522

    CPC分类号： C12Q1/44 ,  A61K31/00 ,  C12Q1/6883 ,  C12Q2600/158

    摘要： The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further concerns the compounds, genes, cells, plasmids or compositions useful for implementing the hereinabove methods. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or experimental target.

    摘要翻译： 本发明涉及生物学，遗传学和医学领域。 特别地，它涉及用于神经变性疾病，特别是肌萎缩性侧索硬化症的检测，表征和/或治疗（或治疗）的新方法。 本发明同样涉及用于鉴定或筛选在这些疾病中活跃的化合物的方法。 本发明还涉及可用于实施上述方法的化合物，基因，细胞，质粒或组合物。 特别地，本发明描述了PDE4B在这些疾病中的作用及其作为治疗，诊断或实验目标的用途。

    Histone deacetylase: novel molecular target of neurotoxicity
    16.
    发明申请
    Histone deacetylase: novel molecular target of neurotoxicity 审中-公开
    组蛋白脱乙酰酶：新型分子靶点的神经毒性

    公开(公告)号：US20050009030A1

    公开(公告)日：2005-01-13

    申请号：US10502754

    申请日：2003-03-25

    申请人： Fabien Schweighoffer ,  Annelies Resink

    发明人： Fabien Schweighoffer ,  Annelies Resink

    IPC分类号： G01N33/50 ,  A61K31/00 ,  A61K31/7088 ,  A61P25/00 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/34 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566

    CPC分类号： A61K31/00 ,  A61K31/7088 ,  C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention concerns the field of biology, genetics and medicine. It particularly pertains to new methods for detecting, characterising and/or treating neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention also pertains to methods for identifying or screening for compounds active in these diseases. The invention also relates to the compounds, genes, cells, plasmids or compositions useful for implementing said methods. The invention particularly describes the role of the histone deacetylases, and particularly histone deacetylase 2, in these diseases and its use as a therapeutic, diagnostic or experimental target.

    摘要翻译： 本发明涉及生物学，遗传学和医学领域。 它特别涉及用于检测，表征和/或治疗神经变性疾病，特别是肌萎缩性侧索硬化的新方法。 本发明还涉及鉴定或筛选这些疾病中活性物质的方法。 本发明还涉及可用于实施所述方法的化合物，基因，细胞，质粒或组合物。 本发明特别描述了组蛋白脱乙酰酶，特别是组蛋白脱乙酰酶2在这些疾病中的作用及其作为治疗，诊断或实验目标的用途。

    QUALITATIVE DIFFERENTIAL SCREENING
    18.
    发明申请
    QUALITATIVE DIFFERENTIAL SCREENING 审中-公开
    定性差异筛选

    公开(公告)号：US20100144555A1

    公开(公告)日：2010-06-10

    申请号：US12641194

    申请日：2009-12-17

    申请人： Bruno TOCQUE ,  Laurent Bracco ,  Florence Edon ,  Fabien Schweighoffer

    发明人： Bruno TOCQUE ,  Laurent Bracco ,  Florence Edon ,  Fabien Schweighoffer

    IPC分类号： C40B50/14 ,  C40B50/02

    CPC分类号： C12N15/1072 ,  C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2539/105 ,  C12Q2565/501 ,  C12Q2537/113 ,  C12Q2521/301

    摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.

    摘要翻译： 本发明涉及用于鉴定和/或克隆代表与选择性剪接事件相关的定性差异的核酸区域的方法和/或在两个生理情境之间的位于RNA转录基因组区域中的插入，缺失的方法，其包括衍生自测试的RNA的杂交 来自参考情况的cDNA的情况和/或来自测试情况的​​cDNA的双链杂交和/或来自参考情况的cDNA的双链杂交; 以及鉴定和/或克隆代表定性差异的核酸。 本发明还涉及表示通过上述方法获得的两种生理情况之间的定性差异的核酸组合物或组，以及它们作为探针的用途，用于鉴定感兴趣的基因或分子，或者仍然例如在药物基因组学的方法中，以及 分子相对于其治疗和/或毒性作用。 本发明还涉及使用拼接RNA的调节作为用于预测分子毒性和/或功效的标记物，以及作为药物基因组学中的标记物。

    Qualitative Differential Screening
    19.
    发明申请
    Qualitative Differential Screening 有权
    定性差异筛选

    公开(公告)号：US20100144550A1

    公开(公告)日：2010-06-10

    申请号：US12622364

    申请日：2009-11-19

    申请人： Fabien Schweighoffer ,  Laurent Bracco ,  Bruno Tocque

    发明人： Fabien Schweighoffer ,  Laurent Bracco ,  Bruno Tocque

    IPC分类号： C40B40/06

    CPC分类号： C12Q1/6809 ,  C12Q2537/113 ,  C12Q2539/105 ,  C12Q2565/501 ,  C12Q2521/301

    摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.

    摘要翻译： 本发明涉及用于鉴定和/或克隆代表与选择性剪接事件相关的定性差异的核酸区域的方法和/或在两个生理情境之间的位于RNA转录基因组区域中的插入，缺失的方法，其包括衍生自测试的RNA的杂交 来自参考情况的cDNA的情况和/或来自测试情况的​​cDNA的双链杂交和/或来自参考情况的cDNA的双链杂交; 以及鉴定和/或克隆代表定性差异的核酸。 本发明还涉及表示通过上述方法获得的两种生理情况之间的定性差异的核酸组合物或组，以及它们作为探针的用途，用于鉴定感兴趣的基因或分子，或者仍然例如在药物基因组学的方法中，以及 分子相对于其治疗和/或毒性作用。 本发明还涉及使用拼接RNA的调节作为用于预测分子毒性和/或功效的标记物，以及作为药物基因组学中的标记物。